Asha Therapeutics (Asha), announced today the appointment of Kirsten Flowers to its Board of Directors.
Asha’s PRISM™ technology has resulted in a pipeline of assets that treats neurological disease by considering neuronal deterioration and loss from multiple vantage points. Within Asha’s pipeline, lead asset ASHA-091 is a first-in-class, near clinic-ready custom-designed brain penetrant compound that restores the mitochondrial network, promoting cell survival over cell death in a number of neurological conditions.
Sam Shrivastava, Asha’s Founder and CEO, noted, “Kirsten Flowers is a seasoned executive whose extensive experience within pharma and biotech will be tremendously additive to Asha as we progress our robust pipeline of assets towards clinic. Her proven strategic and operational expertise from early stage drug development through commercialization and acquisition will provide valuable expertise as Asha continues to advance our portfolio.”
Ms. Flowers said, “I have been impressed by Asha’s ability to efficiently develop multiple, innovative assets and see significant potential of their proprietary PRISM™ platform. I am honored to join the Board of Directors and look forward to collaborating with Asha’s talented team and Board as they advance their first-in-class portfolio into the clinic with the goal of addressing multiple neurological diseases of high unmet need.”
Ms. Flowers most recently served as the Chief Commercial & Corporate Strategy officer for Kura Oncology and brings more than 20 years of pharmaceutical and biotech experience in developing innovative product and pipeline strategies to increase enterprise value, leading successful product launches, managing P&Ls, and helping to recruit, build, and motivate executive teams in both large pharma and smaller biotech organizations. Prior to Kura Oncology, Kirsten served as the Sr. Vice-President of Commercial Operations at Array Biopharma, where she built and led the commercial organization that delivered the successful launch of Braftovi® + Mektovi® ultimately resulting in an $11.4 billion company acquisition by Pfizer. Before joining Array, she held several ascending leadership positions within Pfizer including the U.S. commercial lead for the launch of the blockbuster drugs IBRANCE® in breast cancer and INLYTA® in renal cell carcinoma. Kirsten also serves on the Board of Directors of Comera Life Sciences (Nasdaq: CMRA) and PMV Pharmaceuticals, Inc. (Nasdaq: PMVP). Kirsten earned her MBA from Harvard Business School, and her BS in Molecular & Cellular Biology and Psychology from the University of Arizona.
Kommentare